Tofacitinib, Citrate Salt (Tasocitinib Citrate, CP-690550 Citrate, CP-690550-10, Xeljanz, CAS 540737-29-9), >99%

LC Laboratories' Product Number T-1399 - Tofacitinib, Citrate Salt (Tasocitinib Citrate, CP-690550 Citrate, CP-690550-10, Xeljanz, CAS 540737-29-9), >99% - for research use only. Tofacitinib is a novel Janus kinase 3 (JAK3) inhibitor. JAK3 is a critical cytoplasmic tyrosine kinase in the signaling pathways of multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are associated with various T cell functions. Preclinical and clinical data strongly support that Tofacitinib, as an immunosuppressant, prevents organ transplant rejection and alleviates the symptoms of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriasis. Tofacitinib showed greater antiproliferative and pro-apoptotic activity against murine multipotent factor-dependent cell Patersen-erythropoietin receptor (FDCP-EpoR) cells harboring JAK2(V617F) compared with JAK2(WT). JAK3 plays an important role in pulmonary eosinophilia in the allergic mouse model. Tofacitinib, as a JAK3 inhibitor, represents a potential therapy for treatment of allergic conditions associated with airway eosinophilia including asthma and rhinitis. Tofacitinib was evaluated in murine collagen-induced (CIA) and rat adjuvant-induced (AA) models of rheumatoid arthritis (RA). Tofacitinib dose-dependently reduced endpoints of disease in both RA models. The compound also inhibited inflammatory cell influx and joint damage. Tofacitinib effectively blocked allograft vasculopathy in the rat model of aorta transplantation by inhibiting JAK3. Combination treatment of Tofacitinib with mycophenolate mofetil (MMF) significantly improved allograft survival in nonhuman primates compared to treatment with MMF alone. Tofacitinib citrate is the active ingredient in the drug product sold under the trade name Xeljanz®. This drug is currently approved in at least one country for use in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate; THE TOFACITINIB, CITRATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT XELJANZ®, AND IS NOT FOR HUMAN USE.

• Supplier: LC Laboratories
• Product #: T-1399
• Sku #: T-1399_5g